MBP and myeloid sarcoma: The actual therapeutic strategy is to enhance regulatory power of T-cells: three TCR families, mainly β variable (BV) five and BV6 and to a lesser extent BV13S1, are normally expressed by MBP specific T-cells in the blood, CSF and brain of MS patients (Kotzin et al., 1991).